June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Altered CD8+ T cell function in human non-infectious uveitis
Author Affiliations & Notes
  • Sima Hirani
    NEI, NIH, Bethesda, MD
  • Ping Chen
    NEI, NIH, Bethesda, MD
  • Shayma Jawad
    NEI, NIH, Bethesda, MD
  • Ian Thompson
    NEI, NIH, Bethesda, MD
  • Baoying Liu
    NEI, NIH, Bethesda, MD
  • Lai Wei
    NEI, NIH, Bethesda, MD
  • H Nida Sen
    NEI, NIH, Bethesda, MD
  • Richard Lee
    School of clinical sciences, University of Bristol, Bristol, United Kingdom
  • Robert Nussenblatt
    NEI, NIH, Bethesda, MD
  • Footnotes
    Commercial Relationships Sima Hirani, None; Ping Chen, None; Shayma Jawad, None; Ian Thompson, None; Baoying Liu, None; Lai Wei, None; H Nida Sen, None; Richard Lee, Genentech (C); Robert Nussenblatt, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2026. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sima Hirani, Ping Chen, Shayma Jawad, Ian Thompson, Baoying Liu, Lai Wei, H Nida Sen, Richard Lee, Robert Nussenblatt; Altered CD8+ T cell function in human non-infectious uveitis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2026.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Although CD8+ T cells are primarily implicated in the clearance of viral infections, they have also recently been shown to be a key determinant of clinical prognosis in patients with non-ocular autoimmune diseases. This challenges the conventional paradigm of CD4+ T cell driven autoimmunity, and raises new questions about the role of CD8+ cells in non-infectious inflammation. We therefore interrogated the phenotype and function of CD8+ cells in patients with sight threatening autoimmune uveitis.

Methods: Fresh whole blood from uveitis patients (n=25) and healthy controls (HCs, n=25) was analyzed using flow cytometry. Three subsets of CD8+ cells were distinguished based on surface expression of CD45RA, CD28 and CCR7, representing naïve (CD28+CCR7+CD45RA+), effector memory (CD28+CCR7-CD45RA-), and late differentiated (CD28-CCR7-CD45RA+) cells. The cytotoxic potential of these subsets was then assessed by CD107a expression, and functional killing was quantified by determining the percentage of CFSE+Propidium Iodide+ cells after 6 hours of CD8+ cell co-culture with a CFSE labeled target K562 cell line. Intracellular expression of the transcription factor T-bet , which is a master regulator of CD8+ effector function, was also assessed by flow cytometry.

Results: The proportions of all three CD8+ cell subsets were similar in both uveitis patients and HCs (CD28+CCR7+ ~25%, CD28+CCR7- ~33%, and CD28+CCR7+ ~25%). However, there was a significantly higher percentage of CD107a+ CD8+ cells in uveitis patients (p=0.03). CD8+ cells from uveitis patients also demonstrated a greater capacity to kill target cells (10% vs 3% in HCs) and, in addition, the percentage of cells expressing T-bet was significantly increased in effector memory CD8+ cells from uveitis patients (p<0.0001). A higher percentage of CD8+ cells from uveitis patients were TNF-α+ and IFN-γ+ (62% vs 43% in HCs) but a lower percentage of cells expressed IL-2 (13% vs 25% in HCs).

Conclusions: The increased expression of CD107a and T-bet in effector memory (CD28+CCR7-CD45RA-) CD8+ T cells from uveitis patients indicates a greater capacity for cytotoxicity and this is reflected in enhanced CD8+ T cell killing. This is the first report of altered CD8+ cell function in patients with sight-threatening non-infectious uveitis, and further investigations are now needed to determine whether this contributes to the pathogenesis of intraocular inflammation.

Keywords: 557 inflammation • 746 uveitis-clinical/animal model  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×